Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Unusually-High Trading Volume – What’s Next?

Posted by Ethan Ryder on Jul 9th, 2026

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) shares saw an uptick in trading volume on Thursday . 302,556 shares were traded during mid-day trading, an increase of 126% from the previous session’s volume of 134,092 shares.The stock last traded at $12.1050 and had previously closed at $12.20.

Analyst Ratings Changes

Separately, Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, June 23rd. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Fresenius SE & Co. presently has a consensus rating of “Buy”.

Get Our Latest Stock Analysis on FSNUY

Fresenius SE & Co. Stock Performance

The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 0.41. The stock’s 50 day moving average price is $11.42 and its two-hundred day moving average price is $13.04. The firm has a market capitalization of $27.33 billion, a PE ratio of 16.17 and a beta of 0.63.

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $6.75 billion during the quarter, compared to analysts’ expectations of $6.79 billion. Fresenius SE & Co. had a net margin of 6.55% and a return on equity of 10.09%. On average, equities analysts expect that Fresenius SE & Co. will post 1.03 earnings per share for the current year.

Fresenius SE & Co. Company Profile

(Get Free Report)

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.